Stockreport

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Milestone achieved in Scribe and Lilly’s ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseasesAchievement valida [Read more]